Clinical trial NCT00391157 - References

Multiple Myeloma — VELCADEXA: Velcade and Dexamethasone in Multiple Myeloma

Citation(s)

•   Adams J, Palombella VJ, Sausville EA, Johnson J, Destree A, Lazarus DD, Maas J, Pien CS, Prakash S, Elliott PJ
  Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res. 1999 Jun 1;59(11):2615-22.
•   Alexanian R, Barlogie B, Tucker S
  VAD-based regimens as primary treatment for multiple myeloma. Am J Hematol. 1990 Feb;33(2):86-9.
•   Alexanian R, Dimopoulos M
  The treatment of multiple myeloma. N Engl J Med. 1994 Feb 17;330(7):484-9. Review.
•   Alexanian R, Dimopoulos MA, Delasalle K, Barlogie B
  Primary dexamethasone treatment of multiple myeloma. Blood. 1992 Aug 15;80(4):887-90.
•   Alexanian R, Weber D, Giralt S, Dimopoulos M, Delasalle K, Smith T, Champlin R
  Impact of complete remission with intensive therapy in patients with responsive multiple myeloma. Bone Marrow Transplant. 2001 May;27(10):1037-43.
•   Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet JG, Rossi JF, Casassus P, Maisonneuve H, Facon T, Ifrah N, Payen C, Bataille R
  A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome. N Engl J Med. 1996 Jul 11;335(2):91-7.
•   Baldwin AS
  Control of oncogenesis and cancer therapy resistance by the transcription factor NF-kappaB. J Clin Invest. 2001 Feb;107(3):241-6. Review.
•   Bataille R, Harousseau JL
  Multiple myeloma. N Engl J Med. 1997 Jun 5;336(23):1657-64. Review.
•   Beg AA, Baltimore D
  An essential role for NF-kappaB in preventing TNF-alpha-induced cell death. Science. 1996 Nov 1;274(5288):782-4.
•   Bladé J, Samson D, Reece D, Apperley J, Björkstrand B, Gahrton G, Gertz M, Giralt S, Jagannath S, Vesole D
  Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol. 1998 Sep;102(5):1115-23.
•   Case DC Jr, Lee DJ 3rd, Clarkson BD
  Improved survival times in multiple myeloma treated with melphalan, prednisone, cyclophosphamide, vincristine and BCNU: M-2 protocol. Am J Med. 1977 Dec;63(6):897-903.
•   Driscoll J
  The role of the proteasome in cellular protein degradation. Histol Histopathol. 1994 Jan;9(1):197-202. Review.
•   Goldberg AL, Stein R, Adams J
  New insights into proteasome function: from archaebacteria to drug development. Chem Biol. 1995 Aug;2(8):503-8. Review.
•   Greenlee RT, Murray T, Bolden S, Wingo PA
  Cancer statistics, 2000. CA Cancer J Clin. 2000 Jan-Feb;50(1):7-33.
•   Gregory WM, Richards MA, Malpas JS
  Combination chemotherapy versus melphalan and prednisolone in the treatment of multiple myeloma: an overview of published trials. J Clin Oncol. 1992 Feb;10(2):334-42.
•   Hideshima T, Richardson P, Chauhan D, Palombella VJ, Elliott PJ, Adams J, Anderson KC
  The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res. 2001 Apr 1;61(7):3071-6.
•   Huang YW, Hamilton A, Arnuk OJ, Chaftari P, Chemaly R
  Current drug therapy for multiple myeloma. Drugs. 1999 Apr;57(4):485-506. Review.
•   Koepp DM, Harper JW, Elledge SJ
  How the cyclin became a cyclin: regulated proteolysis in the cell cycle. Cell. 1999 May 14;97(4):431-4. Review.
•   Longo D
  Plasma cell disorders. In: Fauce A, et al. Ed. Harrison's Principles of Internal Medicine. 14th Ed. New York, New York: Mc Graw-Hill; 1998: 712-718.
•   McConkey DJ, Pettaway C, Elliott P, et al
  The proteasome as a new drug target in metastatic prostate cancer. ATMDACC 7th Annual Genitourinary Oncology Conference, 1998.
•   Millenium Pharmaceuticals, Inc
  (PS-341) Investigator's Brochure, Version 5.0, 2001
•   Nadal E, Giné E, Bladé J, Esteve J, Rosiñol L, Fernández-Avilés F, Marin P, Martinez C, Rovira M, Urbano-Ispizua A, Carreras E, Montserrat E
  High-dose therapy/autologous stem cell transplantation in patients with chemosensitive multiple myeloma: predictors of complete remission. Bone Marrow Transplant. 2004 Jan;33(1):61-4.
•   Oken MM
  Management of Myeloma: Current and Future Approaches. Cancer Control. 1998 May;5(3):218-225.
•   Palombella VJ, Rando OJ, Goldberg AL, Maniatis T
  The ubiquitin-proteasome pathway is required for processing the NF-kappa B1 precursor protein and the activation of NF-kappa B. Cell. 1994 Sep 9;78(5):773-85.
•   Raje N, Anderson K
  Thalidomide--a revival story. N Engl J Med. 1999 Nov 18;341(21):1606-9.
•   Read MA, Neish AS, Luscinskas FW, Palombella VJ, Maniatis T, Collins T
  The proteasome pathway is required for cytokine-induced endothelial-leukocyte adhesion molecule expression. Immunity. 1995 May;2(5):493-506.
•   Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, Rajkumar SV, Srkalovic G, Alsina M, Alexanian R, Siegel D, Orlowski RZ, Kuter D, Limentani SA, Lee S, Hideshima T, Esseltine DL, Kauffman M, Adams J, Schenkein DP, Anderson KC
  A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med. 2003 Jun 26;348(26):2609-17.
•   Richter-Ruoff B, Wolf DH
  Proteasome and cell cycle. Evidence for a regulatory role of the protease on mitotic cyclins in yeast. FEBS Lett. 1993 Dec 20;336(1):34-6.
•   Sherr CJ
  Cancer cell cycles. Science. 1996 Dec 6;274(5293):1672-7. Review.
•   Smith ML, Newland AC
  Treatment of myeloma. QJM. 1999 Jan;92(1):11-4. Review.
•   Westin J
  Conventional chemotherapy in multiple myeloma. Pathol Biol (Paris). 1999 Feb;47(2):169-71.
•   Zetter BR
  Adhesion molecules in tumor metastasis. Semin Cancer Biol. 1993 Aug;4(4):219-29. Review.

VELCADEXA: A National, Multi-Center, Open-Label Study of Pretransplant Induction With Alternating VELCADE and Dexamethasone (VEL/Dex) in Younger (< 65 Yrs) Untreated Multiple Myeloma Patients.

Details for clinical trial NCT00391157